ArticleOncotarget2017
Prognostic significance of total metabolic tumor volume on
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.PloS one · 2019Pooled it
- Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.Haematologica · 2022Trial
- Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis.Current oncology (Toronto, Ont.) · 2026Article
- Radiomics based onQuantitative imaging in medicine and surgery · 2025Article
- Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma.Annals of hematology · 2024Article
- Semi-supervised learning towards automated segmentation of PET images with limited annotations: application to lymphoma patients.Physical and engineering sciences in medicine · 2024Article
- TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images - a multi-center generalizability analysis.European journal of nuclear medicine and molecular imaging · 2024Article
- The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma.European radiology · 2024Article
- Baseline and interimFrontiers in oncology · 2024Article
- Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).Japanese journal of radiology · 2023Article
- Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset.Scientific reports · 2023Article
- Review
- Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma.Cancers · 2022Article
- Article
- Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin's lymphoma.Scientific reports · 2021Article
- Radiotherapy in Follicular Lymphoma Staged byBiomedicines · 2021Article
- SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.Blood advances · 2020Article
- Texture Analysis Improves the Value of PretreatmentContrast media & molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to determine the prognostic significance of metabolic parameters on pre-treatment MATERIALS AND
methodsFrom September 2009 to December 2014, DLBCL patients who had received FDG PET/CT scans for staging were enrolled. The maximal standardized uptake value of tumor (SUVt) was recorded. The metabolic tumor volume (MTV) was the volume of lesion with an elevated SUV greater than 2.5. The total lesion glycolysis (TLG) was the sum of the products of MTV and mean SUV in all measured lesions. Univariate and multivariate analyses were used to assess the prognostic significance of maximal SUVt, total MTV, TLG and other clinical parameters.
resultsThere were 118 patients enrolled in this study. The median follow-up time was 28.7 months. The 5-year progression-free survival (PFS) for patients with higher and lower total MTV was 32.3% and 66.0% respectively (
conclusionsAn elevated total MTV was a predictor for shorter PFS and OS in patients with DLBCL receiving rituximab-containing therapy, independent of IPI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.